Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating

Earlier the aforesaid month, Syndax Pharmaceuticals besides released its Q3 2025 net report, wherever the institution disclosed that it achieved full gross of $45.9 million, which was a 21% sequential maturation propelled by 2 cardinal medicines: Revvvi Forge and Nick Timbo, some characterized arsenic archetypal and best-in-class therapies. The company’s commercialized strategy is showing occurrence with beardown diligent uptake and sustained maturation imaginable for some products.

Nick Timbo unsocial saw a nett gross summation of 27% implicit the anterior 4th and is annualizing astatine ~$200 million. Revvvi Forge is rapidly expanding its addressable marketplace pursuing its FDA support for relapse-refractory NPM1-mutated AML, successful summation to its archetypal KMT2A-rearranged acute leukemia indication. Its presumption successful the attraction scenery was further solidified by its summation to the NCCN guidelines.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is simply a commercial-stage biopharmaceutical institution that develops therapies for the attraction of cancer.

While we admit the imaginable of SNDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.